Events
Discussion Forum for Best of DAAG 2018: Emotions and Decision Analysis
SDP Free Webinar
22 Aug, 2018 | 8:00 am PT / 11:00 am ET
Discussants:
Somik Raha, Ulu Ventures
Eyas Raddad, Eli Lilly
Elayne Ko, Pfizer
Abstract:
This Webinar continues to explore and progress the topic of Emotions and DA, a presentation voted a "Best of DAAG" at the April 2018 conference. The Webinar will recap key learnings from neuroscience research and the importance of emotions in decision-making, followed by a brief talk on Evolution of Emotions and DA including an illustrative example in the context of business decision-making. The majority of time will be dedicated to an interactive dialogue, led by Somik Raha, Eyas Raddad and Elayne Ko, to address questions submitted by the DA community to help decision professionals work towards better facilitation of decision opportunities and advise decision-makers in business and personal decision-making contexts.
22 Aug, 2018 | 8:00 am PT / 11:00 am ET
Discussants:
Somik Raha, Ulu Ventures
Eyas Raddad, Eli Lilly
Elayne Ko, Pfizer
Abstract:
This Webinar continues to explore and progress the topic of Emotions and DA, a presentation voted a "Best of DAAG" at the April 2018 conference. The Webinar will recap key learnings from neuroscience research and the importance of emotions in decision-making, followed by a brief talk on Evolution of Emotions and DA including an illustrative example in the context of business decision-making. The majority of time will be dedicated to an interactive dialogue, led by Somik Raha, Eyas Raddad and Elayne Ko, to address questions submitted by the DA community to help decision professionals work towards better facilitation of decision opportunities and advise decision-makers in business and personal decision-making contexts.
Add this event to your calendar
|
Location
GoToWebinar
|
|
Dates
Aug 22, 2018
08:00 AM - 09:00 AM |
|
Contact
Hilda Cherekdjian
|
|
Respondent Email
|
NOTE:
In the June 2018 webinar, in a presentation titled Emotions and Decision Analysis, Dr. Raha discusses advances in neuroscience that would cause us to re-examine how we practice Decision Analysis and, in particular, how we engage with values. You may find the replay of this presentation here :
Please note, It is not a requirement to view this webinar ahead of the August presentation.
Discussants
Somik Raha, Ulu Ventures
Dr. Somik Raha is a Decision Analysis PhD alum from the Department of Management Science and Engineering at Stanford University. His PhD dissertation titled "Achieving Clarity on Value” focused on aligning decisions with core values, and he has continued to build on that research and share it publicly. He was Head of Product at SmartOrg for 6 years, where he led a team to build the world’s first Excel-based Portfolio Decision Analysis platform on the cloud. At Ulu Ventures, Somik works at the intersection of values, decision analysis and technology.
Eyas Raddad, Eli Lilly & Co.
Eyas is a Senior Research Advisor at Lilly Research Laboratories, Decision Science and Portfolio Strategy department. He is a seasoned drug discovery and development researcher, strategist and innovator. Since he joined Eli Lilly and Company in 2001, he applied sophisticated data analytics and strategic frameworks to improve decision making in drug discovery and development process, and led a group of scientist in his technical area of PK/PD. He later moved to Chorus, the industry-renowned innovative early development engine, where he established the PK/PD function, and helped advance tens of novel drugs to a decisive proof-of-concept stage, setting a record that is the envy of the industry. He continues to pursue efforts that help increase the productivity of the drug discovery and development innovation cycle. Over his career, he implemented Decision Analytic techniques in drug development applications. In 2017, Eyas established and led Research Decision Analytics function in Lilly Research Laboratories, with a mission that includes portfolio management, decision consulting and decision education.
A native of Jordan, Eyas holds a BS in Pharmacy (University of Jordan; 1997), and a PhD in Pharmaceutics (University of Georgia; 2001). To aid his innovation and transformation agenda, Eyas completed an MBA from MIT-Sloan School of Management in 2013.
Elayne Ko, Pfizer
Elayne Ko currently holds a Director position at the Portfolio and Decision Analysis (PDA) group within Pfizer, Inc. She has over 15 years of experience in applying decision analysis to investment decision-making under uncertainties. Her focus is primarily within the pharmaceutical industry; in particular, drug research and development (R&D) decisions, long-term planning, and disease area/portfolio prioritization. She works with both the R&D teams and senior management making funding decisions. Elayne has worked – in the consulting and corporate settings – across several industries including healthcare information technology, oil & gas and mining. Prior to Pfizer, Elayne held positions as Portfolio Manager at Siemens Health Services Strategy Group, Manager at Deloitte Financial Advisory Services LLP, and Senior Consultant within the Applied Decision Analysis (ADA) group of PricewaterhouseCoopers (PwC). Elayne obtained a BSc in Management Sciences and MSc in Decision Sciences from The London School of Economics.
